Corporate Responsibility Report

Overview

The report highlights Royalty Pharma's upgrade to an AA MSCI ESG rating and its enhanced responsible investment due diligence incorporating human rights. It describes the launch of an Employee Engagement Committee, expanded professional development, approximately $9.2 million in non-profit donations and employee volunteering. Environmentally, the report discloses 23,266 metric tons of Scope 3 investment emissions for 2024 and reproduces Apex's limited-assurance verification declaration.

Document

Report type: Sustainability Report
Class: Dedicated
Scope: Full report
Fiscal year: 2024
Period: 1 January 2024 – 31 December 2024
Publication date: 14 April 2025
Language: English
Pages
File size

Standards

GRI
SASB
TCFD
ISSB
ESRS
Integrated Reporting Framework
GHG Protocol
EU Taxonomy
CDP
Other

Commitments

UN Global Compact
UN Guiding Principles
Science Based Targets initiative

Ratings

GRI level

Materiality

Assessment
Basis

Assurance

Provider
Level
Standard
Scope
Statement included
Metrics assured

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services